# Haihe Biopharma Co., Ltd. clinical trials: 20 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials with Haihe Biopharma Co., Ltd. as lead sponsor, 4 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Haihe Biopharma Co., Ltd.: 20 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/haihe-biopharma-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 4
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 17, 2026 | NCT07824505 | Lucitanib (AL3810) in Patients With Advanced Thymic Carcinoma After Chemotherapy | Haihe Biopharma Co., Ltd. | Phase 2 | Completed | Advanced Thymic Carcinoma | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07824505) |
| May 16, 2025 | NCT06975618 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth... | Haihe Biopharma Co., Ltd. | Phase 1/2 | Recruiting | PIK3CA-Related Overgrowth Spectrum (PROS), PIK3CA-related Vascular Malformations (PRVM) | 141 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06975618) |
| April 4, 2025 | NCT06909877 | Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma | Haihe Biopharma Co., Ltd. | Phase 1/2 | Recruiting | Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06909877) |
| August 18, 2022 | NCT05507294 | Single Dose Glumetinib in Healthy Chinese Male Subjects | Haihe Biopharma Co., Ltd. | Phase 1 | Completed | Healthy Volunteers | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05507294) |
| September 14, 2021 | NCT05043922 | A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma | Haihe Biopharma Co., Ltd. | Phase 2 | Active not recruiting | Ovarian Cancer, Recurrent Cancer | 93 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05043922) |
| April 23, 2021 | NCT04856371 | Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer | Haihe Biopharma Co., Ltd. | Phase 1 | Unknown | Advanced Breast Cancer | 228 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04856371) |
| February 10, 2021 | NCT04746612 | First in Human Study to Evaluate the Safety, Tolerability of HH30134 in Advanced Solid Tumors | Haihe Biopharma Co., Ltd. | Phase 1 | Terminated | Advanced Solid Tumors | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04746612) |
| October 14, 2020 | NCT04586335 | Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. | Haihe Biopharma Co., Ltd. | Phase 1 | Terminated | Ovarian Cancer, Breast Cancer, Solid Tumor, Prostate Cancer, Endometrial Cancer | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04586335) |
| May 15, 2020 | NCT04390737 | Evaluate the Safety and Clinical Activity of HH2853 | Haihe Biopharma Co., Ltd. | Phase 1/2 | Recruiting | FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor | 254 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04390737) |
| April 8, 2020 | NCT04338243 | Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive... | Haihe Biopharma Co., Ltd. | Phase 1/2 | Unknown | Negative T790M Mutation and Met Amplification | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04338243) |
| February 17, 2020 | NCT04270591 | Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer | Haihe Biopharma Co., Ltd. | Phase 1/2 | Recruiting | C-Met Exon 14 Mutation | 183 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04270591) |
| February 5, 2020 | NCT04254471 | This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients | Haihe Biopharma Co., Ltd. | Phase 2/3 | Unknown | Extensive-stage Small Cell Lung Cancer | 313 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04254471) |
| December 13, 2019 | NCT04198818 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors | Haihe Biopharma Co., Ltd. | Phase 1/2 | Terminated | Advanced Tumors, Melanoma, Non-Small-Cell Lung Cancer, Erdheim-Chester Disease, Other RAS/RAF/MEK/ERK Mutated Tumors | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04198818) |
| June 4, 2018 | NCT03544905 | Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33 | Haihe Biopharma Co., Ltd. | Phase 1 | Completed | Advanced Solid Tumors | 206 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03544905) |
| March 15, 2018 | NCT03466268 | Study to Evaluate the Safety and Anti-tumor Activity of SCC244 | Haihe Biopharma Co., Ltd. | Phase 1 | Completed | Advanced Solid Tumor | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03466268) |
| March 7, 2018 | NCT03457532 | A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors | Haihe Biopharma Co., Ltd. | Phase 1 | Completed | Advanced Solid Tumor | 177 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03457532) |
| August 24, 2017 | NCT03260179 | Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810 | Haihe Biopharma Co., Ltd. | Phase 1 | Unknown | Advanced Solid Tumor, Advanced/Metastatic Colorectal Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03260179) |
| April 17, 2017 | NCT03117101 | Study of the AL3810 in the Treatment of Advanced Solid Tumor | Haihe Biopharma Co., Ltd. | Phase 1 | Completed | Advanced Solid Tumors | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03117101) |
| August 17, 2016 | NCT02870036 | Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients... | Haihe Biopharma Co., Ltd. | Phase 1 | Unknown | Advanced Solid Tumor, Advanced/Metastatic Colorectal Cancer | 243 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02870036) |
| April 16, 2013 | NCT01832298 | Study of Simmitecan Hydrochloride in the Treatment of Advanced Solid Tumor | Haihe Biopharma Co., Ltd. | Phase 1 | Completed | Advanced Solid Tumor | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01832298) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 11 |
| Phase 1/2 | 6 |
| Phase 2 | 2 |
| Phase 2/3 | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 7 |
| Unknown | 5 |
| Recruiting | 4 |
| Terminated | 3 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Colorectal Neoplasms | 2 |
| Ovarian Neoplasms | 2 |
| Recurrence | 2 |
| Lymphoma, T-Cell, Peripheral | 2 |
| Thymoma | 1 |
| Small Cell Lung Carcinoma | 1 |
| Melanoma | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Erdheim-Chester Disease | 1 |
| Breast Neoplasms | 1 |
| Prostatic Neoplasms | 1 |
| Endometrial Neoplasms | 1 |
| Hereditary Sensory and Autonomic Neuropathies | 1 |
| Lymphoma, Follicular | 1 |
| Sarcoma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Vegetarian restaurants in the United States](https://specstream.ai/data/businesses/vegetarian-restaurants/united-states)
- [French restaurants in the United States](https://specstream.ai/data/businesses/french-restaurants/united-states)
- [Steakhouses in the United States](https://specstream.ai/data/businesses/steakhouses/united-states)
- [Electronic parts suppliers in the United States](https://specstream.ai/data/businesses/electronic-parts-suppliers/united-states)
- [Real estate law firms in the United States](https://specstream.ai/data/businesses/real-estate-law-firms/united-states)
- [Construction companies in the United States](https://specstream.ai/data/businesses/construction-companies/united-states)
